Profilo
Shawn A. Scranton currently works at Libra Therapeutics, Inc., as President & Chief Executive Officer from 2024.
Dr. Scranton also formerly worked at Kalypsys, Inc., as Director-Translational Medicine from 2005 to 2007, Salmedix, Inc., as Director-Clinical Research & Program from 2001 to 2005, Dura Pharmaceuticals, Inc., as Principal from 1998 to 2000, Baylor College of Medicine, as Faculty Member, Victory Pharma, Inc., as Vice President-Scientific Operations from 2007 to 2012, Pelican, Inc., as Chief Operating Officer & Senior Vice President from 2018 to 2020, Sentynl Therapeutics, Inc., as Chief Scientific Officer & Senior Vice President from 2015 to 2017, and Amber Ophthalmics, as President & Chief Scientific Officer from 2020 to 2024.
Dr. Scranton received his undergraduate degree in 1988 from the University of California San Diego and doctorate degree in 1994 from the University of the Pacific.
Posizioni attive di Shawn A. Scranton
| Società | Posizione | Inizio |
|---|---|---|
Libra Therapeutics, Inc.
Libra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for neurodegenerative diseases | Amministratore Delegato | 01/11/2024 |
Precedenti posizioni note di Shawn A. Scranton
| Società | Posizione | Fine |
|---|---|---|
Amber Ophthalmics
Amber Ophthalmics BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Presidente | 01/06/2024 |
| PFENEX INC. | Direttore operativo | 01/10/2020 |
Sentynl Therapeutics, Inc.
Sentynl Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Direttore Tecnico/Scientifico/R&S | 01/01/2017 |
Victory Pharma, Inc.
Victory Pharma, Inc. Pharmaceuticals: MajorHealth Technology Manufactures prescription pharmaceutical products | Direttore Tecnico/Scientifico/R&S | 02/01/2012 |
Kalypsys, Inc.
Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases | Corporate Officer/Principal | 02/01/2007 |
Formazione di Shawn A. Scranton
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 11 |
|---|---|
Dura Pharmaceuticals, Inc.
Dura Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and markets prescription pharmaceutical products | Health Technology |
Kalypsys, Inc.
Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases | Health Technology |
Salmedix, Inc.
Salmedix, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology and small molecule drugs to treat hematologic malignancies | Health Technology |
University of California San Diego
University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of the Pacific
University of the Pacific Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Baylor College of Medicine
Baylor College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Victory Pharma, Inc.
Victory Pharma, Inc. Pharmaceuticals: MajorHealth Technology Manufactures prescription pharmaceutical products | Health Technology |
Pelican Inc
Pelican Inc Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical therapeutics and vaccines | Health Technology |
Sentynl Therapeutics, Inc.
Sentynl Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Libra Therapeutics, Inc.
Libra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for neurodegenerative diseases | Health Technology |
Amber Ophthalmics
Amber Ophthalmics BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
















